Ibruxen 140 mg is a pharmaceutical product identified as a 140 mg ibrutinib capsule manufactured by Everest Pharmaceuticals Ltd. in Bangladesh.
Product identity
| Attribute | Information |
|---|---|
| Product name | Ibruxen |
| Active ingredient | Ibrutinib |
| Strength | 140 mg |
| Dosage form | Capsule |
| Route | Oral |
| Drug class | BTK inhibitor |
| Therapeutic category | Targeted cancer therapy |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Reference product | IMBRUVICA |
| Active-substance developer | Pharmacyclics/Janssen development collaboration |
What is ibrutinib?
Ibrutinib is a small-molecule inhibitor of BTK. It forms a covalent bond with a cysteine residue in the BTK active site, producing sustained inhibition of BTK signaling. BTK participates in B-cell receptor and cytokine-receptor signaling.
Ibruxen and IMBRUVICA
IMBRUVICA is the established branded ibrutinib product associated with the original U.S. approval. The medicine was jointly developed and commercialized by Janssen and Pharmacyclics.
Ibruxen is not the same commercial product as IMBRUVICA. The two products share the active ingredient ibrutinib, but product-specific manufacturing, packaging, excipients and authorization details may differ.
Why 140 mg matters
One Ibruxen capsule contains 140 mg of ibrutinib. Depending on the indication, a prescribed daily dose may require more than one 140 mg capsule. Current U.S. IMBRUVICA labeling, for example, uses 420 mg daily for adult CLL/SLL and WM and 560 mg historically for certain indications, while current U.S. labeling has withdrawn MCL and MZL indications.
Professional supervision
Ibrutinib can affect bleeding, immune defense, cardiovascular function, blood-cell counts and liver function. Medication interactions, particularly involving CYP3A, can substantially alter exposure.